** Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 3.4% to $7.54
** NTLA reports Q1 net loss of $1.10 per share, narrower than the net loss of $1.12 a year ago
** Posts Q1 collaboration revenue of $16.63 million, compared with $28.9 million a year ago
** Co says it has cash and cash equivalents of $707.1 million as of March 31, with runway expected into H1 2027
** Including session's moves, stock down 35.4% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。